Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis IgG1K monoclonal antibody Interleukin-17A neutralizing
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 100
Healthy volunteers: no

Brief summary:
This study aims to confirm if patients with a specific biomarker might have a better response to secukinumab treatment. To meet this purpose, exploratory biomarker studies will be done. The goals of these exploratory studies are to (1) find biomarkers that will identify persons with rheumatoid arthritis who will have the best possible response to secukinumab and (2) to identify persons who will have fewer side effects in order to maximize their benefit from secukinumab.

Detailed description:

Arms:
arm 1: 10 mg/kg intravenous (I.V.) arm 2: Placebo I.V.

Interventions: intervention 1: Placebo intervention 2: Secukinumab
Intervention descriptions: intervention 1: Matching placebo to secukinumab I.V. intervention 2: In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.

Protocol document: